Sugi Predict

Sugi Predict / Compounds / SCHEMBL3420501

SCHEMBL3420501

SCHEMBL3420501

CCOC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OGFOD1 Q8N543 1/20 0.71
▸ EGLN2 Q96KS0 1/20 0.71
▸ EGLN1 Q9GZT9 1/20 0.71
▸ EGLN3 Q9H6Z9 1/20 0.71
▸ HIF1AN Q9NWT6 1/20 0.71
▸ KMT2A Q03164 4/20 0.49
▸ MAPK1 P28482 3/20 0.49
▸ MEN1 O00255 3/20 0.49
▸ NPSR1 Q6W5P4 3/20 0.49
▸ MAPT P10636 2/20 0.49
▸ XBP1 P17861 2/20 0.49
▸ ATM Q13315 1/20 0.49
▸ ALDH1A1 P00352 4/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ OPRM1 P35372 1/20 0.41
▸ OPRK1 P41145 1/20 0.41
▸ OGFRL1 Q5TC84 1/20 0.41
▸ LMNA P02545 3/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL15419211 0.98 OGFOD1 (0.71) OGFOD1EGLN2EGLN1EGLN3HIF1AN
SCHEMBL3419515 0.93 OGFOD1 (0.65) OGFOD1EGLN2EGLN1EGLN3HIF1AN
SCHEMBL3419522 0.93 OGFOD1 (0.65) OGFOD1EGLN2EGLN1EGLN3HIF1AN
SCHEMBL31216690 0.90 OGFOD1 (0.76) OGFOD1EGLN2EGLN1EGLN3HIF1AN
SCHEMBL3421268 0.89 OGFOD1 (0.56) OGFOD1EGLN2EGLN1EGLN3HIF1AN
SCHEMBL22003118 0.89 OGFOD1 (0.56) OGFOD1EGLN2EGLN1EGLN3HIF1AN
SCHEMBL1641893 0.85 OGFOD1 (0.51) OGFOD1EGLN2EGLN1EGLN3HIF1AN
SCHEMBL1642058 0.84 OGFOD1 (0.49) OGFOD1EGLN2EGLN1EGLN3HIF1AN
SCHEMBL3419289 0.83 EGLN3 (0.50) OGFOD1EGLN2EGLN1EGLN3HIF1AN
SCHEMBL3420522 0.83 EGLN3 (0.50) OGFOD1EGLN2EGLN1EGLN3HIF1AN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140336383-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2014-11-13 — — US claimed
WO-2024022998-A1 PROCESS FOR PREPARING DAPRODUSTAT AND COCRYSTALS THEREOF INKE, S.A. (ES) 2024-02-01 — — WO disclosed
US-20230227414-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2023-07-20 — — US disclosed
US-11643397-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2023-05-09 — — US disclosed
US-20210347740-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2021-11-11 — — US disclosed
US-20200157055-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2020-05-21 — — US disclosed
US-10336711-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2019-07-02 — — US disclosed
US-20180305323-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2018-10-25 — — US disclosed
US-10035779-B2 Prolyl hydroxylase inhibitors GlaxoSmithKline, LLC (US) 2018-07-31 — — US disclosed
EP-2037922-B9 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2017-08-23 — — EP disclosed
US-20140336383-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2014-11-13 — — US disclosed
US-8815884-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2014-08-26 — — US disclosed
US-20140024666-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2014-01-23 — — US disclosed
EP-2037922-B1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2014-01-22 — — EP disclosed
US-8557834-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2013-10-15 — — US disclosed
US-20130072487-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-03-21 — — US disclosed
US-8324208-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2012-12-04 — — US disclosed
US-20100113444-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-05-06 — — US disclosed
EP-2037922-A2 PROLYL HYDROXYLASE INHIBITORS SmithKline Beecham Corporation (US) 2009-03-25 — — EP disclosed
WO-2007150011-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024666-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN3, EGLN2 OGFOD1 22/4885EGLN2 3/4885EGLN1 6/4885
US-11643397-B2 Prolyl hydroxylase inhibitors HIF1AN, EGLN3, EGLN2 OGFOD1 22/4885EGLN2 3/4885EGLN1 6/4885
US-20210347740-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 OGFOD1 22/4885EGLN2 3/4885EGLN1 6/4885
US-20130072487-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN3, EGLN2 OGFOD1 22/4885EGLN2 3/4885EGLN1 6/4885
US-20100113444-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN3, EGLN2 OGFOD1 26/4885EGLN2 3/4885EGLN1 6/4885
US-10336711-B2 Prolyl hydroxylase inhibitors HIF1AN, EGLN3, EGLN2 OGFOD1 22/4885EGLN2 3/4885EGLN1 6/4885
US-20140336383-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN3, EGLN2 OGFOD1 22/4885EGLN2 3/4885EGLN1 6/4885
US-20200157055-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 OGFOD1 22/4885EGLN2 3/4885EGLN1 6/4885
US-20180305323-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 OGFOD1 22/4885EGLN2 3/4885EGLN1 6/4885
US-10035779-B2 Prolyl hydroxylase inhibitors HIF1AN, EGLN3, EGLN2 OGFOD1 22/4885EGLN2 3/4885EGLN1 6/4885
US-20230227414-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 OGFOD1 22/4885EGLN2 3/4885EGLN1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.